Myriad Genetics (MYGN) Operating Leases (2019 - 2026)

Myriad Genetics (MYGN) has 8 years of Operating Leases data on file, last reported at $84.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $84.1 million, down 3.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.1 million (down 3.78% YoY), and the FY2025 annual result was $83.0 million, down 5.57% from the prior year.
• Operating Leases advanced to $84.1 million in Q1 2026 per MYGN's latest filing, from $83.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $130.9 million in Q4 2022 and troughed at $5.9 million in Q1 2023.
• A 5-year average of $77.8 million and a median of $87.4 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 95.21% in 2023, then jumped 1498.31% in 2024.
• A 5-year view of Operating Leases shows it stood at $130.9 million in 2022, then declined by 25.59% to $97.4 million in 2023, then fell by 9.75% to $87.9 million in 2024, then retreated by 5.57% to $83.0 million in 2025, then advanced by 1.33% to $84.1 million in 2026.
• Business Quant data shows MYGN's Operating Leases at $84.1 million in Q1 2026, $83.0 million in Q4 2025, and $84.9 million in Q3 2025.